公开(公告)号：US20100015221A1

公开(公告)日：2010-01-21

申请号：US12097867

申请日：2006-12-20

申请人： Norishige Takami ,  Shinsuke Nagira ,  Yasushi Okada ,  Noriko Okada ,  Takayuki Ohwaki ,  Reiko Nishijima

发明人： Norishige Takami ,  Shinsuke Nagira ,  Yasushi Okada ,  Noriko Okada ,  Takayuki Ohwaki ,  Reiko Nishijima

IPC分类号： A61K9/20 ,  A61K31/07 ,  A61K31/59 ,  A61K31/122 ,  A61K31/121 ,  A61K31/355 ,  A61P43/00

CPC分类号： A61K9/2054 ,  A61K9/0056 ,  A61K9/16 ,  A61K9/2018 ,  A61K9/2077 ,  A61K31/07 ,  A61K31/121 ,  A61K31/122 ,  A61K31/355 ,  A61K31/59

摘要： The present invention provides an orally rapid disintegrating tablet preparation that contains a high dose of a fat-soluble active ingredient, that exhibits excellent disintegration characteristics in the oral cavity, and that can be produced by a dry tabletting method. The present invention also provides a method of producing an orally rapid disintegrating tablet preparation. The present invention discloses an orally rapid disintegrating tablet preparation that is obtained by tabletting a uniform mixture prepared by mixing saccharide alcohol, crystalline cellulose, and a lubricant with a granule that has been produced by the adsorption of a fat-soluble active ingredient on a porous material.

摘要翻译： 本发明提供一种口服快速崩解片剂，其含有高剂量的在口腔中具有优异的崩解特性的脂溶性活性成分，并且可以通过干燥压片法制造。 本发明还提供一种口服快速崩解片剂的制备方法。 本发明公开了一种口服快速崩解片剂，其通过将通过将脂溶性活性成分吸附在多孔性物质上制成的颗粒将糖醇，结晶纤维素和润滑剂混合而成的均匀混合物 材料。

公开(公告)号：US20060063701A1

公开(公告)日：2006-03-23

申请号：US11202449

申请日：2005-08-11

申请人： Hidechika Okada ,  Noriko Okada

发明人： Hidechika Okada ,  Noriko Okada

IPC分类号： A61K38/10 ,  C07K7/08

CPC分类号： C07K7/08 ,  A61K38/00 ,  C07K14/472

摘要： PL37 (RAARISLGPRICKAFTE [SEQ ID NO: 2]) is an Antisense Homolgoy Box peptide composed of amino acids 37 to 53 of C5a-anaphylatoxin. Complementary peptides, ASGAPAPGPAGPLRPMF (Pep-A [SEQ ID NO: 1]) and ASTAPARAGLPRLPKFF (Pep-B [SEQ ID NO: 3]) were designed and characterized. Pep-A bound to PL37 and to C5a with very slow dissociation, whereas Pep-B failed to bind at all. C5a was inactivated by 7 nM or more of Pep-A and this concentration of Pep-A inhibited induction of intracellular Ca++ influx in neutrophils. Patch clamp studies also showed the effectiveness of Pep-A in C5a-receptor-expressing neuroblastoma cells. Pep-A administration prevented rats from C5a-mediated rapid lethal shock. A-Pep-A (Pep-A acetylated with alanine at the amino-terminus) was more stable in vivo and showed stronger inhibition of inflammatory reactions in mice and rats. Chemical modification of Pep-A (e.g., acetylation, or single or multiple amino acid replacement, insertion, or deletion within the native Pep-A sequence) will yield effective inhibitors, and will often improve inhibitory function on C5a anaphylatoxin. In such modified constructs it will often be desired to conserve some or all 5 prolines found in Pep-A to preserve inhibitory function on C5a.

摘要翻译： PL37（RAARISL​​GPRICKAFTE [SEQ ID NO：2]）是由C5a-过敏毒素的氨基酸37至53组成的反义同源盒肽。 设计并表征互补肽ASGAPAPGPAGPLRPMF（Pep-A [SEQ ID NO：1]）和ASTAPARAGLPRLPKFF（Pep-B [SEQ ID NO：3]）。 Pep-A与PL37和C5a结合非常缓慢的解离，而Pep-B根本无法结合。 C5a被7nM或更多的Pep-A灭活，并且该浓度的Pep-A抑制嗜中性粒细胞内细胞内Ca ++流入的诱导。 补体钳研究还显示Pep-A在表达C5a受体的神经母细胞瘤细胞中的有效性。 Pep-A治疗阻止大鼠C5a介导的快速致死性休克。 A-Pep-A（在氨基末端用丙氨酸乙酰化的Pep-A）在体内更稳定，并且在小鼠和大鼠中表现出更强的炎症反应抑制。 Pep-A的化学修饰（例如，乙酰化，或天然Pep-A序列内的单个或多个氨基酸置换，插入或缺失）将产生有效的抑制剂，并且将经常改善对C5a过敏毒素的抑制功能。 在这种修饰的构建体中，通常需要保存Pep-A中发现的一些或全部5个脯氨酸以保持对C5a的抑制功能。

公开(公告)号：US07763708B2

公开(公告)日：2010-07-27

申请号：US11202449

申请日：2005-08-11

申请人： Hidechika Okada ,  Noriko Okada

发明人： Hidechika Okada ,  Noriko Okada

IPC分类号： A61K38/10

CPC分类号： C07K7/08 ,  A61K38/00 ,  C07K14/472

摘要： PL37 (RAARISLGPRCIKAFTE [SEQ ID NO: 2]) is an Antisense Homology Box peptide composed of amino acids 37 to 53 of C5a-anaphylatoxin. Complementary peptides, ASGAPAPGPAGPLRPMF (Pep-A [SEQ ID NO: 1]) and ASTAPARAGLPRLPKFF (Pep-B [SEQ ID NO: 3]) were designed and characterized. Pep-A bound to PL37 and to C5a with very slow dissociation, whereas Pep-B failed to bind at all. C5a was inactivated by 7 nM or more of Pep-A and this concentration of Pep-A inhibited induction of intracellular Ca++ influx in neutrophils. Patch clamp studies also showed the effectiveness of Pep-A in C5a-receptor-expressing neuroblastoma cells. Pep-A administration prevented rats from C5a-mediated rapid lethal shock. A-Pep-A (Pep-A acetylated with alanine at the amino-terminus) was more stable in vivo and showed stronger inhibition of inflammatory reactions in mice and rats. Chemical modification of Pep-A (e.g., acetylation, or single or multiple amino acid replacement, insertion, or deletion within the native Pep-A sequence) will yield effective inhibitors, and will often improve inhibitory function on C5a anaphylatoxin. In such modified constructs it will often be desired to conserve some or all 5 prolines found in Pep-A to preserve inhibitory function on C5a.

摘要翻译： PL37（RAARISL​​GPRCIKAFTE [SEQ ID NO：2]）是由C5a-过敏毒素的氨基酸37〜53构成的反义同源盒肽。 设计并表征互补肽ASGAPAPGPAGPLRPMF（Pep-A [SEQ ID NO：1]）和ASTAPARAGLPRLPKFF（Pep-B [SEQ ID NO：3]）。 Pep-A与PL37和C5a结合非常缓慢的解离，而Pep-B根本无法结合。 C5a被7nM或更多的Pep-A灭活，并且这种浓度的Pep-A抑制嗜中性粒细胞中细胞内Ca ++流入的诱导。 补体钳研究还显示Pep-A在表达C5a受体的神经母细胞瘤细胞中的有效性。 Pep-A治疗阻止大鼠C5a介导的快速致死性休克。 A-Pep-A（在氨基末端用丙氨酸乙酰化的Pep-A）在体内更稳定，并且在小鼠和大鼠中表现出更强的炎症反应抑制。 Pep-A的化学修饰（例如，乙酰化，或天然Pep-A序列内的单个或多个氨基酸置换，插入或缺失）将产生有效的抑制剂，并且将经常改善对C5a过敏毒素的抑制功能。 在这种修饰的构建体中，通常需要保存Pep-A中发现的一些或全部5个脯氨酸以保持对C5a的抑制功能。

公开(公告)号：US07513654B2

公开(公告)日：2009-04-07

申请号：US11433598

申请日：2006-05-12

申请人： Noriko Okada

发明人： Noriko Okada

IPC分类号： F21V7/00

CPC分类号： F21S41/37 ,  F21S41/143 ,  F21S41/147 ,  F21S41/285 ,  F21S41/321 ,  F21S41/322 ,  F21S41/36 ,  F21S41/365 ,  F21V7/06 ,  F21V7/08

摘要： A lighting device for a vehicle has a light-emitting element disposed on an optical axis, a first reflection surface for reflecting light emitted from the light-emitting element in an outer radial direction of the optical axis, and a second reflection surface for reflecting the light reflected by the first reflection surface forward. A cross-sectional shape of the first reflection surface taken along a predetermined plane including the optical axis is an ellipse. The ellipse has a light-emitting center as a first focus and an axis line crossing the optical axis as a major axis. The second reflection surface is disposed between the first focus and a second focus of the ellipse. A cross-sectional shape of the second reflection surface taken along the predetermined plane is a parabola having the second focus of the ellipse as a focus and a point located forward of the focus as a vertex.

摘要翻译： 车辆用照明装置具有配置在光轴上的发光元件，在光轴的外径方向上反射从发光元件射出的光的第一反射面和反射光的第二反射面 第一反射面向前反射的光。 沿着包括光轴的预定平面截取的第一反射表面的横截面形状是椭圆形。 椭圆具有作为第一焦点的发光中心和与光轴交叉的轴线作为长轴。 第二反射面设置在椭圆的第一焦点和第二焦点之间。 沿着预定平面截取的第二反射表面的横截面形状是具有作为焦点的椭圆的第二焦点和位于焦点的前方作为顶点的点的抛物线。

公开(公告)号：US20060140964A1

公开(公告)日：2006-06-29

申请号：US10520016

申请日：2003-06-30

申请人： Hidechika Okada ,  Noriko Okada

发明人： Hidechika Okada ,  Noriko Okada

IPC分类号： A61K39/42 ,  C07K16/10

CPC分类号： C07K16/28 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  Y10S530/809

摘要： A human IgM monoclonal antibody responding to HIV-infected cells too, which is characterized by lysing activated human lymphocytes, etc. under the mediation by a homologous human complement, is obtained. Using the thus obtained monoclonal antibody, it is intended to provide an immune reaction controlling remedy, etc. containing the human IgM monoclonal antibody which responds specifically to activated lymphocytes and induces cell lysis under the mediation by a homologous complement. Using the human IgM monoclonal antibody responding to activated human lymphocytes, it is also intended to provide an HIV remedy, etc. characterized by lysing and eliminating activated lymphocytes to thereby treat transplantation rejection and autoimmune diseases caused by an over-response of T lymphocytes as well as HIV infection

摘要翻译： 获得了响应于HIV感染细胞的人IgM单克隆抗体，其特征在于通过同源人补体在介导下裂解活化的人淋巴细胞等。 使用如此获得的单克隆抗体，旨在提供含有人IgM单克隆抗体的免疫反应控制药物，其特异性响应于活化的淋巴细胞，并在同源补体的介导下诱导细胞裂解。 使用对活化的人淋巴细胞作出反应的人IgM单克隆抗体，还旨在提供HIV疗法等，其特征在于裂解和消除活化的淋巴细胞，从而治疗由T淋巴细胞过度反应引起的移植排斥反应和自身免疫性疾病 作为艾滋病毒感染

公开(公告)号：US4381259A

公开(公告)日：1983-04-26

申请号：US208466

申请日：1980-11-19

申请人： Itomi Homma ,  Noriko Okada

发明人： Itomi Homma ,  Noriko Okada

IPC分类号： C11D1/34 ,  A61K8/00 ,  A61K8/40 ,  A61K8/41 ,  A61K8/42 ,  A61K8/46 ,  A61K8/55 ,  A61K8/73 ,  A61K8/81 ,  A61K8/84 ,  A61K8/86 ,  A61Q5/02 ,  A61Q5/12 ,  C11D3/36 ,  C11D1/14

CPC分类号： A61Q5/02 ,  A61K8/556 ,  A61K8/731 ,  A61K8/817 ,  A61K8/84 ,  A61K8/86 ,  A61Q5/12 ,  A61K2800/5426

摘要： A liquid hair shampoo which comprises a shampoo base of surfactant effective for washing hair, 0.1 to 2.5 wt. % of anionic phosphoric acid ester surface active agent and 0.05 to 2.5 wt. % of a cationic polymer effective for conditioning hair.

摘要翻译： 一种液体洗发剂，其包含用于洗发的头发的洗发剂基质，0.1至2.5重量％ ％的阴离子磷酸酯表面活性剂和0.05〜2.5wt。 ％的阳离子聚合物有效调理头发。

公开(公告)号：US07595050B2

公开(公告)日：2009-09-29

申请号：US10519855

申请日：2003-06-30

申请人： Hidechika Okada ,  Noriko Okada

发明人： Hidechika Okada ,  Noriko Okada

IPC分类号： A61K39/42

CPC分类号： C07K16/28 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/73

摘要： A monoclonal antibody falling within the category of human IgM which specifically recognizes HIV-infected cells and induces apoptosis is obtained. Using the obtained antibody, it is intended to provide a remedy for patients suffering from HIV-infection, which contains as the active ingredient a human IgM antibody capable of specifically reacting with HIV-infected cells, inducing apoptosis in the infected cells and thus disrupting the cells, etc.

摘要翻译： 属于特异性识别HIV感染细胞并诱导凋亡的人IgM类别的单克隆抗体。 使用获得的抗体旨在为患有HIV感染的患者提供补救措施，其包含作为活性成分的能够与HIV感染的细胞特异性反应的人IgM抗体，诱导感染的细胞中的细胞凋亡，从而破坏 细胞等

公开(公告)号：US20060292160A1

公开(公告)日：2006-12-28

申请号：US10519855

申请日：2003-06-30

申请人： Hidechika Okada ,  Noriko Okada

发明人： Hidechika Okada ,  Noriko Okada

IPC分类号： A61K39/42 ,  C07K16/10

CPC分类号： C07K16/28 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/73

摘要： A monoclonal antibody falling within the category of human IgM which specifically recognizes HIV-infected cells and induces apoptosis is obtained. Using the obtained antibody, it is intended to provide a remedy for patients suffering from HIV-infection, which contains as the active ingredient a human IgM antibody capable of specifically reacting with HIV-infected cells, inducing apoptosis in the infected cells and thus disrupting the cells, etc.

摘要翻译： 属于特异性识别HIV感染细胞并诱导凋亡的人IgM类别的单克隆抗体。 使用获得的抗体旨在为患有HIV感染的患者提供补救措施，其包含作为活性成分的能够与HIV感染的细胞特异性反应的人IgM抗体，诱导感染的细胞中的细胞凋亡，从而破坏 细胞等

公开(公告)号：US20060275826A1

公开(公告)日：2006-12-07

申请号：US11414713

申请日：2006-04-28

申请人： Hidechika Okada ,  Noriko Okada

发明人： Hidechika Okada ,  Noriko Okada

IPC分类号： G01N33/53

CPC分类号： G01N33/6854 ,  C07K14/001 ,  C07K2318/20

摘要： A method for detecting an antigen using a complementary peptide reactive to a target protein as an artificial antibody.

摘要翻译： 使用与靶蛋白反应的互补肽作为人造抗体来检测抗原的方法。

公开(公告)号：US06190863B1

公开(公告)日：2001-02-20

申请号：US09077091

申请日：1998-05-19

申请人： Hidechika Okada ,  Noriko Okada

发明人： Hidechika Okada ,  Noriko Okada

IPC分类号： C12Q170

CPC分类号： C07K16/18 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/28

摘要： The present invention is directed to a sugar-chain-recognizing antibody which belongs to the IgM isotype and which recognizes Gg4Cer(Gal&bgr;1-3GalNAc&bgr;1-4Gal&bgr;1-4Glc&bgr;Cer) or GM2 which appears on HIV infected cells, as well as to a therapeutics for HIV diseases containing those IgMs.

摘要翻译： 本发明涉及属于IgM同种型并识别出现在HIV感染细胞上的Gg4Cer（Galbeta1-3GalNAcbeta1-4Galbeta1-4GlcbetaCer）或GM2的糖链识别抗体，以及用于HIV疾病的治疗剂 含有这些IgM。